研究单位：[1]Eisai Co.,Ltd.[2]Peking University Sixth Hospital Beijing,Beijing,China[3]Xuanwu Hospital Capital Medical University Beijing,Beijing,China[4]Daping Hospital Chongqing,Chongqing,China[5]The First Affiliated Hospital of Jinan University Guangzhou,Guangdong,China[6]The First Hospital of Hebei Medical University Shijiazhuang,Hebei,China[7]The Third Hospital of Hebei Medical University Shijiazhuang,Hebei,China[8]Henan Mental Health Center Xinxiang,Henan,China[9]Wuhan Mental Health Center Wuhan,Hubei,China[10]Nanjing Brain Hosptial Nanjing,Jiangsu,China[11]The Second Affiliated Hospital of Soochow University Suzhou,Jiangsu,China[12]The Second Affiliated Hospital of Nanchang University Nanchang,Jiangxi,China[13]Jilin First University Affiliated Hospital Changchun,Jilin,China[14]Inner Mongolia Autonomous Region Peoples Hospital Hohhot,Mongolia,China[15]Tangdu Hospital Xian,Shaanxi,China[16]Shandong Provincial Qianfushan Hospital Jinan,Shandong,China[17]Huashan Hospital Fudan University Shanghai,Shanghai,China[18]Shanghai Mental Health Center Shanghai,Shanghai,China[19]First Hospital of Shanxi Medical University Taiyuan,Shannxi,China[20]West China Hospital Chengdu,Sichuan,China[21]Tianjin Anding Hospital Tianjin,Tianjin,China[22]Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital Taoyuan,Taipei,Taiwan[23]Taipei Veterans General Hospital Taipei,Taiwan
研究目的：
The primary purpose of this study is to confirm using polysomnography (PSG) that lemborexant 10 milligram (mg) is superior to placebo on objective sleep onset as assessed by latency to persistent sleep (LPS) during the last 2 nights of 1 month of treatment in participants with insomnia disorder.
